VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

rMV-S + rMV-N vaccine
Vaccine Information
  • Vaccine Name: rMV-S + rMV-N vaccine
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Type: Mixed vaccine of two viral vector vaccines
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Antigen: codon-optimised spike glycoprotein (S), SARS-CoV nucleocapsid protein (N) (Liniger et al., 2008)
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Description: Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (Weingartl et al., 2004).
Host Response

Mouse Response

  • Host Strain: Ifnartm-CD46Ge transgenic mice(Liniger et al., 2008)
  • Vaccination Protocol: Mice were immunized with 0.5 × 10^4 pfu of each recombinant virus per mouse (Liniger et al., 2008)
  • Immune Response: Induction of both humoral neutralizing and cellular responses against SARS-CoV, and neutralizing immunity against MV. (Liniger et al., 2008)
References
Liniger et al., 2008: Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marty RR, Wiegand M, Weibel S, Kelvin D, Rota PA, Naim HY. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine. 2008; 26(17); 2164-2174. [PubMed: 18346823].
Weingartl et al., 2004: Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D, Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. Journal of virology. 2004; 78(22); 12672-12676. [PubMed: 15507655].